Shared Biologic Pathways Between Alzheimer Disease and Major Depression: A Systematic Review of MicroRNA Expression

Ana Paula Mendes-Silva1, Kelly Silva Pereira1, Gesiane Thamire Tolentino-Araujo1

  • 1Graduate Program in Molecular Medicine, Federal University of Minas Gerais School of Medicine, Belo Horizonte, MG, Brazil.

Abstract

Insights

Major depressive disorder (MDD) and Alzheimer disease (AD) share common neurobiologic abnormalities. Key links include genomic integrity, proteostasis, immune regulation, and neurotrophic support.

Area of Science:

  • Neurobiology
  • Genetics
  • Psychiatry

Background:

  • Clinical and epidemiological data suggest shared neurobiological underpinnings between major depressive disorder (MDD) and Alzheimer disease (AD).
  • Understanding these commonalities may elucidate disease mechanisms and identify therapeutic targets for both conditions.

Purpose of the Study:

  • To systematically review and identify microRNAs (miRNAs) abnormally expressed in both AD and MDD.
  • To analyze the regulatory patterns, target genes, and biological pathways associated with these shared miRNAs.

Main Methods:

  • Systematic literature review to identify miRNAs dysregulated in AD and MDD.
  • Bioinformatic analysis to determine common miRNAs, their target genes, and associated biological processes.

Main Results:

  • Seven miRNAs (e.g., hsa-let-7f-5p, hsa-miR-191-5p) were found to be commonly dysregulated in both AD and MDD.
  • These miRNAs target 45 genes involved in crucial biological pathways including proteostasis, genomic integrity, immune-inflammatory control, and neurotrophic support.

Conclusions:

  • Maintenance of genomic integrity, proteostasis control, immune-inflammatory regulation, and neurotrophic support represent key neurobiological links between MDD and AD.
  • A hypothetical model is proposed to explain the interaction between MDD, aging, and AD development.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.1K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
830
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.5K
Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.6K